233 related articles for article (PubMed ID: 37983208)
41. Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Kujawski L; Talpaz M
Leuk Lymphoma; 2007 Dec; 48(12):2310-22. PubMed ID: 18067005
[TBL] [Abstract][Full Text] [Related]
42. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
Jabbour E; Kantarjian H; Cortes J
Semin Hematol; 2010 Oct; 47(4):344-53. PubMed ID: 20875551
[TBL] [Abstract][Full Text] [Related]
43. [Research Advance of
Zhou LY; Zhou LY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):585-588. PubMed ID: 37096538
[TBL] [Abstract][Full Text] [Related]
44. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
45. The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1β in vascular endothelium in association with downregulation of miR-3p.
Sukegawa M; Wang X; Nishioka C; Pan B; Xu K; Ohkawara H; Hamasaki Y; Mita M; Nakamura K; Okamoto M; Shimura H; Ohta M; Ikezoe T
Leuk Res; 2017 Jul; 58():83-90. PubMed ID: 28501737
[TBL] [Abstract][Full Text] [Related]
46. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
Salih J; Hilpert J; Placke T; Grünebach F; Steinle A; Salih HR; Krusch M
Int J Cancer; 2010 Nov; 127(9):2119-28. PubMed ID: 20143399
[TBL] [Abstract][Full Text] [Related]
47. [State-of-the-art management of CML in 2015 and future prospects].
Kimura S
Rinsho Ketsueki; 2015 Oct; 56(10):2005-14. PubMed ID: 26458439
[TBL] [Abstract][Full Text] [Related]
48. Ever-advancing chronic myeloid leukemia treatment.
Kimura S; Ando T; Kojima K
Int J Clin Oncol; 2014 Feb; 19(1):3-9. PubMed ID: 24258348
[TBL] [Abstract][Full Text] [Related]
49. [Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].
Miyazaki S
Rinsho Ketsueki; 2021; 62(8):1024-1028. PubMed ID: 34497188
[TBL] [Abstract][Full Text] [Related]
50. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
[TBL] [Abstract][Full Text] [Related]
51. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G
Blood; 2009 Sep; 114(10):2168-71. PubMed ID: 19589924
[TBL] [Abstract][Full Text] [Related]
52. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Kantarjian H; Cortes J
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S37-42; quiz S43-S44. PubMed ID: 18397680
[TBL] [Abstract][Full Text] [Related]
53. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Jabbour E; Hochhaus A; Cortes J; La Rosée P; Kantarjian HM
Leukemia; 2010 Jan; 24(1):6-12. PubMed ID: 19798095
[TBL] [Abstract][Full Text] [Related]
54. BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Haguet H; Douxfils J; Chatelain C; Graux C; Mullier F; Dogné JM
TH Open; 2018 Jan; 2(1):e68-e88. PubMed ID: 31249931
[TBL] [Abstract][Full Text] [Related]
55. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
56. Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.
Atallah E; Mauro MJ; Hochhaus A; Boquimpani C; Minami Y; Maheshwari VK; Saini L; Corbin R; Réa D
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6247-6262. PubMed ID: 36707445
[TBL] [Abstract][Full Text] [Related]
57. Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors.
Kuo YH; Wei SH; Jiang JH; Chang YS; Liu MY; Fu SL; Huang CF; Lin WJ
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830455
[TBL] [Abstract][Full Text] [Related]
58. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Jabbour E; Cortes J; O'Brien S; Giles F; Kantarjian H
Semin Hematol; 2007 Jan; 44(1 Suppl 1):S25-31. PubMed ID: 17292738
[TBL] [Abstract][Full Text] [Related]
59. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors.
Haddad FG; Kantarjian H
J Natl Compr Canc Netw; 2024 Feb; 22(1):. PubMed ID: 38394773
[TBL] [Abstract][Full Text] [Related]
60. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Piccaluga PP; Paolini S; Martinelli G
Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
